Foundation Medicine is rolling out a cancer genomics software system for next-generation sequencing (NGS) tests, building out its offerings amid an increasingly stringent reimbursement environment.
The brains behind Naurex, a drug developer acquired by Allergan for $560 million up front, have put the band back together, starting a new biotech with their old company's technology and setting their sights on central nervous system disorders.
Google is bringing on Thomas Insel, former director of the National Institute of Mental Health, to work for its burgeoning Life Science group and apply the company's technologies to mental illness.
Medtronic snagged a grant from the Israeli government to launch a digital medicine incubator in the country, expanding its international footprint and joining other tech companies to nurture promising startups in the field.
Olympus and Sony are rolling out a high-definition endoscope, months after Sony--Olympus' largest shareholder--announced that it would sell off half its stake in the company amid growing scrutiny over Olympus' duodenoscope devices.
Royal Philips aims to roll out a series of programs for chronic diseases that marry consumer-oriented device data with the electronic medical record. The idea is to give patients and healthcare providers access to all the relevant data and analysis to improve self-care and medical care.
Novo Nordisk and MIT's Langer Lab announced a three-year collaboration focused on developing next-generation drug delivery devices for the administration of peptides using noninjectable methods. There is an option to extend the deal for an additional three years.
The biotech arm of Merck KGaA is building a 16,000-square-meter addition to accommodate 200 research staffers, noting that the facility should be ready in 2017.
Dimension Therapeutics is preparing to execute the next carefully planned step in its evolution, filing for a $115 million IPO close to 5 months after its crossover round landed. The filing came just days after the FDA accepted Cambridge, MA-based Dimension's IND for its lead gene therapy program, targeting a genetic fix for hemophilia B.
Last fall, Acacia Pharma's virtual crew cheered the late-stage success of a drug designed to prevent postoperative nausea and vomiting by bringing in strategic advisers to help hammer out a path forward. And evidently, they concluded that setting out to raise $230 million on the London Stock Exchange was the right way to go.